Clinical Trials on Advanced Solid Cancer in Japan

Total 1374 results

AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca

Terminated

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
Novartis Pharmaceuticals

Terminated

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Cancer | Solid Tumor | Advanced Solid Tumor

Japan
AstraZeneca
MedImmune LLC

Completed

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
Novartis Pharmaceuticals

Completed

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

Cancer | Advanced Solid Tumor

Japan
AbbVie

Completed

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Advanced Solid Tumors Cancer

Japan
Daiichi Sankyo Co., Ltd.

Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Solid Tumor | Metastatic Solid Tumor | Advanced Cancer

Japan, United States, Canada
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
AstraZeneca

Completed

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

Advanced Solid Tumor

Japan
AstraZeneca

Active, not recruiting

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
Incyte Biosciences Japan GK

Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-1123a in Advanced Solid Tumours

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Terminated

Open Label Study of DS-5573a

Advanced Solid Malignant Tumors

Japan
Toshihiko Doi
Merck Sharp & Dohme LLC; Oncolys BioPharma Inc

Completed

Special Combination of OBP-301 and Pembrolizumab

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Completed

Phase I Dose Escalating Study of TKI258

Advanced Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

Advanced Solid Tumors

Japan
Eli Lilly and Company
Parexel

Completed

Study of IMC-1121B in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
AstraZeneca

Completed

Open Label, Dose Escalation Phase I Study of AZD2281

Advanced Solid Malignancies

Japan
Genta Incorporated

Unknown

Study of Tesetaxel in Japanese Patients With Solid Tumors

Advanced Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating Safety And Tolerability, Solid Tumor

Advanced Malignant Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Advanced Malignant Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Recruiting

A Study of DS-1471a In Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Eli Lilly and Company

Completed

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumor

Japan
AstraZeneca

Completed

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Advanced Solid Tumours

Japan
Novartis Pharmaceuticals

Completed

A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.

Advanced Solid Tumors

Japan
AstraZeneca

Completed

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Advanced Solid Malignancies

Japan
Novartis

Completed

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
AstraZeneca

Active, not recruiting

MEDI5752 in Japanese Patients With Advanced Solid Tumors.

Advanced Solid Tumors

Japan
Takeda

Completed

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Japan
AstraZeneca

Completed

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Sanofi

Completed

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Kohei Shitara
Ono Pharmaceutical Co. Ltd; Bayer Yakuhin, Ltd.

Completed

Regorafenib and Nivolumab Simultaneous Combination Therapy (REGONIVO)

Advanced and Metastatic Solid Tumor

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors

Japan
Ono Pharmaceutical Co. Ltd

Completed

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
3D Medicines (Sichuan) Co., Ltd.

Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
Novartis Pharmaceuticals

Terminated

Dose Escalation of HSP990 in Japan/Korea

Advanced Solid Tumors

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Completed

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Advanced Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Array Biopharma, now a wholly owned subsidiary...

Completed

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
Astellas Pharma Inc

Completed

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Advanced Malignant Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

A Phase I Study of LEE011 in Asian Patients

Advanced Solid Tumors

Japan

3

Subscribe